Topics

bluebird bio and Novo Nordisk Partner to Develop in vivo Genome Editing Candidates for Hemophilia and Other Severe Genetic Diseases

14:38 EDT 9 Oct 2019 | Speciality Pharma Journal

CAMBRIDGE, Mass. and BAGSVÆRD, Denmark–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including hemophilia. During the three-year research collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the …

Original Article: bluebird bio and Novo Nordisk Partner to Develop in vivo Genome Editing Candidates for Hemophilia and Other Severe Genetic Diseases

NEXT ARTICLE

More From BioPortfolio on "bluebird bio and Novo Nordisk Partner to Develop in vivo Genome Editing Candidates for Hemophilia and Other Severe Genetic Diseases"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...